US2003229202A1PendingUtilityA1
Membrane penetrating peptides and uses thereof
Priority: Aug 25, 2000Filed: Aug 21, 2001Published: Dec 11, 2003
Est. expiryAug 25, 2020(expired)· nominal 20-yr term from priority
A61P 43/00C07K 14/4702C07K 2319/60C07K 2319/50C07K 2319/09C12N 15/62C07K 2319/10C07K 2319/00C07K 2319/03C07K 2319/43C07K 19/00
42
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention is directed to membrane penetrating peptides useful as in viv, ex vivo and in vitro intracellular delivery devices for compound of interest. More particularly, the invention involves identification of membrane penetrating peptides which may be used as protein carriers for delivery of a compound of interest to cells, to methods of delivering a compound of interest attached to membrane penetrating peptides to cells.
Claims
exact text as granted — not AI-modifiedWe claim:
1 . A fusion protein for delivery of a compound of interest into a cell, comprising a membrane penetrating peptide attached to a compound of interest.
2 . The fusion protein according to claim 1 , wherein the membrane penetrating peptide is derived from a nuclear localization sequence, overlaps with a nuclear localization sequence of a mammalian or yeast protein or comprises a sequence —(X—X—X—X) n — where n is an integer 1 to 7, and X each time is independently selected from the group consisting of arginine, histidine or lysine.
3 . The fusion protein according to claim 2 , wherein the nuclear localization sequence is derived from a nuclear protein or transcription factor.
4 . The fusion protein according to claim 3 , wherein the transcription factor is a Period protein.
5 . The fusion protein according to claim 4 , wherein the Period protein is a human Period protein.
6 . The fusion protein according to claim 5 , wherein the mammalian Period protein is human Period1 protein.
7 . The fusion protein according to claim 2 wherein the membrane penetrating peptide comprises the sequence —(X—X—X—X) n — where n is an integer 1 to 7, and X each time is independently selected from the group consisting of arginine, histidine or lysine.
8 . The fusion protein according to claim 7 , wherein n is an integer 1 to 4.
9 . The fusion protein according to claim 8 , wherein n is an integer 1 to 2.
10 . The fusion protein according to claim 1 , wherein the compound of interest is a peptide, protein, chemical entity, nucleic acid, or any modified form thereof.
11 . A method of delivering a compound of interest into a cell, comprising contacting a cell with a fusion protein according to claim 1 .
12 . The method of delivering a compound of interest into a cell in vitro, comprising contacting a cultured cell with a fusion protein according to claim 1 .
13 . The method of delivering a compound of interest into a cell ex vivo, comprising contacting a cell with a fusion protein according to claim 1 and introducing the cell into the body of a patient.
14 . The method of delivering a compound of interest into a cell in vivo, comprising administering to a patient a fusion protein according to claim 1 .
15 . A method for identifying a membrane penetrating peptide, wherein a peptide comprises a sequence —(X—X—X—X) n — where n is an integer 1 to 7, and X each time is independently selected from the group consisting of arginine, histidine or lysine, by generating a conjugate peptide comprising the sequence —(X—X—X—X) n — where n is an integer 1 to 7, and X each time is independently selected from the group consisting of arginine, histidine or lysine, with a detectable protein, adding the conjugate peptide exogenously to a cell and determining if the conjugated peptide is located within the cytoplasm and/or nucleus of the cell.
16 . A method for identifying a membrane penetrating peptide, wherein a peptide comprises a sequence derived from or overlapping with a nuclear localization sequence of a mammalian or yeast protein, by generating a conjugate peptide comprising the part or all of the nuclear localization sequence with a detectable protein, adding the conjugate peptide exogenously to a cell and determining if the conjugated peptide is located within the cytoplasm and/or nucleus of the cell.
17 . The method of delivering a compound of interest into a cell, comprising administering to a cell a fusion protein according to claim 1 , wherein the membrane penetrating peptide comprises a sequence —(X—X—X—X) n — where n is an integer 1 to 7, and X each time is independently selected from the group consisting of arginine, histidine or lysine.
18 . A fusion protein for delivering a compound of interest into a cell, wherein the fusion protein comprises a membrane penetrating peptide comprising a sequence —(X—X—X—X) n — where n is an integer 1 to 7, and X each time is independently selected from the group consisting of arginine, histidine or lysine, and a compound of interest.
19 . The fusion protein of claim 18 , wherein the compound of interest is directly chemically attached to the membrane penetrating peptide or by a linker.
20 . The fusion protein of claim 19 , wherein the linker is an amino acid linker or a polypeptide linker.
21 . The fusion protein of claim 18 , wherein the membrane penetrating protein is produced by recombinant technology, chemical synthesis or degradation of a precursor protein.Join the waitlist — get patent alerts
Track US2003229202A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.